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Abstract A cDNA clone of prostaglandin F synthase (PGFS)
was isolated from human lung by using cDNA of bovine lung-
type PGFS as a probe and its protein expressed in Escherichia
coli was purified to apparent homogeneity. The human PGFS
catalyzed the reduction of prostaglandin (PG) D2, PGH2 and
phenanthrenequinone (PQ), and the oxidation of 9K,11L-PGF2
to PGD2. The kcat/Km values for PGD2 and 9K,11L-PGF2 were
21 000 and 1800 min31 mM31, respectively, indicating that the
catalytic efficiency for PGD2 and 9K,11L-PGF2 was the highest
among the various substrates, except for PQ. The PGFS activity
in the cytosol of human lung was completely absorbed with anti-
human PGFS antiserum. Moreover, mRNA of PGFS was
expressed in peripheral blood lymphocytes and the expression in
lymphocytes was markedly suppressed by the T cell mitogen
concanavalin A. These results support the notion that human
PGFS plays an important role in the pathogenesis of allergic
diseases such as asthma.
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1. Introduction
Prostaglandin (PG) F2 is widely distributed in various or-
gans and exhibits various biological actions such as smooth
muscle contraction of uterus, bronchus and trachea [1], the
initiation of parturition [2] and pain transmission [3]. We dis-
covered PGD2 11-ketoreductase involved in the formation of
PGF2 from PGD2 in rat tissues [4]. The enzyme puri¢ed from
bovine lung is a dual function enzyme, which catalyzes the
reduction of not only PGD2 but also PGH2 on the same
molecule, and we named it PGF synthase (PGFS) (EC
1.1.1.188) [5]. Then, we characterized the enzymatic and mo-
lecular properties of bovine lung [5^9] and liver [10,11]
PGFSs. Although bovine PGFSs had low reductase activity
towards PGE2 and various steroid compounds containing a
keto group and a low oxidase activity for converting 9K,11L-
PGF2 to PGD2, the enzymes exhibited reductase activities
towards various carbonyl compounds, such as phenanthrene-
quinone (PQ), nitrobenzaldehyde (NB) and nitroacetophe-
none, in addition to PGD2 and PGH2. Bovine PGFSs belong
to the aldo-keto reductase (AKR) superfamily based on sub-
strate speci¢city, molecular weight and the amino acid se-
quence. In 1995, Nagase et al. [12] isolated full-length
cDNA clones from size-fractionated cDNA libraries of hu-
man immature myeloid cell line KG-1. The amino acid se-
quence of one clone, KIAA0119, was similar to that of the
AKR family. The nucleotide and deduced amino acid sequen-
ces of KIAA0119 were identical to those of AKR1C3 [13]
except for six nucleotides and two amino acids. AKR1C3
was reported to be a 3K-hydroxysteroid dehydrogenase
(HSD) [13,14], but the enzymatic properties of KIAA0119
were not known. Matsuura et al. [15] examined the enzymatic
properties of AKR1C3. They constructed AKR1C3 by site-
directed mutagenesis of KIAA0119 and reported that
AKR1C3 acted as a PGD2 11-ketoreductase. PGD2 11-keto-
reductase activity is associated with PGFS, but the PGFS ac-
tivity of KIAA0119 and AKR1C3 has not been reported yet.
Moreover, the physiological roles of AKR1C3 and KIAA0119
have not been determined yet. Bovine lung PGFS is abundant
in the contractile interstitial cells in the alveolar septum, based
on the results of immunohistochemical techniques at both
light and electron microscopic levels [16,17], and this implies
that PGFS may play an important physiological role in hu-
man lung tissue. In fact, Beasley et al. reported that 9K,11L-
PGF2 possibly contributes to the bronchoconstrictor e¡ect of
a mast cell-derived mediator in asthma [18]. In this paper, as
an initial approach to clarify the physiological role of human
PGFS, we isolated a cDNA clone of human PGFS from lung
and expressed the protein in Escherichia coli. Furthermore, we
examined the enzymatic properties and described the possible
relationship between PGFS and allergy.
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2. Materials and methods
2.1. Materials
[5,6,8,9,12,14,15-3H]PGD2 (3.7 TBq/mmol) was obtained from Du
Pont-New England Nuclear. [1-14C]PGH2 (2.07 GBq/mmol) was ob-
tained from Daiichi Pure Chemicals (Japan). Authentic PGs were
kindly donated by Ono Pharmaceutical Company.
2.2. cDNA cloning of human PGFS
A human lung 5P-stretch plus cDNA library in Vgt 10 vector was
purchased from Clontech Laboratories (USA). The library (4U106
plaques) was screened by plaque hybridization by using 32P-labelled
full-length cDNA for bovine lung PGFS as a probe [7]. Hybridization
was conducted as described previously [11] and 20 positive clones were
obtained and sequenced by TAKARA (Japan). One clone encoded the
full-length cDNA of human PGFS and was designated as V-hLuFS.
2.3. Expression of human PGFS in E. coli and puri¢cation of its
expressed protein
Two oligonucleotides for N- and C-termini of the open reading
frame amino acid sequences were synthesized, containing EcoRI
(CCGGAATTCAATGGATTCCAAACAGCAGTG) and BamHI
(CGCGGATCCTTAATATTCATCTGAATATG) linkers, respec-
tively. Using V-hLuFS as a template and two primers, we inserted
the DNA ampli¢ed by PCR with Vent DNA polymerase (BioLabs,
USA) into a pUC8 vector. The resultant plasmid DNA (pUC-hLuFS)
was sequenced with an ABI automated DNA sequencer 373A (Perkin
Elmer, USA). E. coli HB101 cells transformed with the plasmid were
cultured at 37‡C overnight and the harvested cells were sonicated in
three volumes of bu¡er A (10 mM potassium phosphate bu¡er, pH
7.0). The lysate was centrifuged at 100 000Ug after 10 000Ug centri-
fugation and was subjected to ammonium sulfate fractionation be-
tween 40 and 75% saturation. The precipitate formed was suspended
in 10 mM Tris-Cl (pH 8.0) and applied onto an Ultrogel AcA 54
column (2.0U85 cm, BioSepra, France). The enzyme active fractions
were applied to a DEAE-Toyopearl column (TOSO, Japan) and the
enzyme was eluted with 10^100 mM Tris-Cl (pH 8.0). About 20-fold
puri¢cation of the recombinant protein was achieved and the homo-
geneity was con¢rmed following sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) and staining with 2D-SILVER
STAINWII ‘DAIICHI’ (Daiichi Pure Chemicals, Japan). The ¢nal pu-
ri¢ed enzyme was suspended in bu¡er A. The recombinant protein
had no amino acid residues additional to those of the native protein.
A polyclonal antibody against human PGFS was raised in a rabbit
with the puri¢ed recombinant enzyme used as the immunogen. West-
ern blot analysis of a sample of each puri¢cation step of the recombi-
nant enzyme was conducted, as described previously [11], by use of
the anti-human PGFS antiserum.
2.4. Enzyme assay
The PGD2 11-ketoreductase, PGH2 9,11-endoperoxide reductase
and reductase activities towards various compounds containing a
keto group, such as PQ, of the recombinant protein were measured
as described previously [5], except that 0.1 M Tris-HCl (pH 8.5) was
used instead of 0.1 M potassium phosphate bu¡er (pH 6.5). The
oxidase activities towards 9K,11L-PGF2 and various hydroxysteroids
were measured spectrophotometrically at 37‡C by following the in-
crease in absorbance at 340 nm in the assay mixture consisting of 0.1
M Tris-HCl (pH 10.0), 80 WM NADP, various concentrations of
each substrate and enzyme in a total volume of 0.5 ml. Protein was
determined according to the method of Lowry et al. [19].
2.5. Immunoabsorption of PGD2 11-ketoreductase activity in human
lung
Human lung tissue was obtained from a patient at the Shiga Med-
ical Center for Adults after informed consent was obtained as a part
of routine diagnostic procedures. The cytosol fraction of the tissue
(650 Wg) was incubated overnight with various concentrations of the
anti-human PGFS antiserum (0^200 Wg) at 4‡C. After addition of
protein G Sepharose (20 Wl), the mixture was incubated at 4‡C for
1 h and centrifuged at 10 000Ug for 15 min. PGD2 11-ketoreductase
activity of the supernatant was measured as described above.
2.6. RT-PCR of human PGFS mRNA
Peripheral blood was obtained from healthy volunteers and lym-
phocyte suspensions were prepared by use of Lymphoprep (Nycomed
Pharma AS, Norway). Peripheral blood lymphocytes (PBL, 107 cells/
well) were incubated for 24 h with or without 25 Wg/ml concanavalin
A (Con A) (Seikagakukogyo, Japan). Total RNA was prepared from
PBL and human lung and RT-PCR of mRNAs was carried out with
PGFS-speci¢c primers: PGFS-F4, 5P-GGTGAGGAACTTTCAC-
CAAC-3P and PGFS-R5, 5P-GGTTGAAGTTTGACACCCCA-3P.
3. Results
3.1. cDNA cloning of human PGFS
Screening of 4U106 plaques of a human lung cDNA library
with the cDNA probe for bovine lung PGFS gave 20 positive
clones. DNA sequencing con¢rmed that one clone harbored a
full-length cDNA for human PGFS, because the deduced ami-
no acid sequence of human PGFS (Fig. 1) showed 76% and
78% identities with those sequences of bovine lung and liver
PGFSs, respectively. As shown in Fig. 1, V-hLuFS contained
an initiation codon and a polyadenylation signal after the stop
codon with an open reading frame of 969 bp encoding 323
amino acids. The calculated molecular weight of the human
PGFS was 36 842 Da, a value similar to those values of bo-
vine lung and liver PGFSs, which are about 36 kDa [7,11].
This enzyme showed a high identity in amino acid sequence
with not only bovine lung and liver PGFSs but also human
liver dihydrodiol dehydrogenase (DD) 1 (88%) [20], DD2
(87%) [20] and DD4 (84%) [21]. Moreover, its sequence was
identical to that of KIAA0119 [12].
3.2. Characterization of recombinant human PGFS
The recombinant protein was expressed in E. coli (HB101)
transformed with pUC-hLuFS and was puri¢ed to apparent
homogeneity as described under Section 2. About 20-fold pu-
ri¢cation of the PGD2 11-ketoreductase activity was achieved
from the lysate of E. coli with a yield of 32%. The speci¢c
activity of the puri¢ed recombinant enzyme was 2 Wmol/min/
mg protein. A sample of each puri¢cation step was subjected
to SDS-PAGE. Silver staining of the gel indicated that a 36.8
kDa protein was produced in the cells harboring pUC-hLuFS
and that the enzyme was puri¢ed to apparent homogeneity
(Fig. 2A). Western blot analysis of each sample revealed that
the 36.8 kDa protein was recognized by anti-human PGFS
antibody (Fig. 2B). The molecular weight of the expressed
enzyme was almost the same as that of the recombinant bo-
vine lung PGFS [8]. No protein from the control E. coli bear-
ing pUC8 vector without the insert DNA interacted with this
antibody (data not shown). The N-terminal amino acid se-
quence of the expressed recombinant protein was identical
to that deduced from the V-hLuFS cDNA without any addi-
tional amino acid residues.
Next, we examined the enzymatic properties of the puri¢ed
recombinant protein. The optimal pH for the reduction of
PGD2 was pH 8^9, di¡erent from that (pH 6.5) for that of
bovine lung and liver PGFSs, and the optimum for the oxi-
dation of 9K,11L-PGF2 was pH 9^10, similar to that of both
bovine PGFSs. The substrate speci¢city of the puri¢ed re-
combinant PGFS was examined at pH 8.5 for the reductase
activity and at pH 10 for the oxidase activity. As shown in
Table 1, the Km and kcat values for PQ were 2 WM and 130
min31, respectively, giving the highest kcat/Km value (138 000
min31 mM31). Although the kcat value for PGD2 was 1/4 of
that for PQ, the Km value for PGD2 was 3 WM, almost the
same as that for PQ, giving a high kcat/Km value (21 200).
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However, the reduction of NB exhibited a high Km value (100-
fold of the Km value for PQ) and low kcat value (0.6-fold of
the kcat value for PQ), giving a low kcat/Km value. On the
other hand, although the oxidation of 9K,11L-PGF2 to
PGD2 showed a high Km value (130 WM), the kcat value was
the highest among the substrates, giving the kcat/Km value of
about 1800 min31 mM31, following those of PQ and PGD2.
Moreover, the expressed human PGFS catalyzed the reduc-
tion of PGH2 to PGF2K and the reductase activity was 8% of
that towards PGD2, indicating that human PGFS is also a
dual function enzyme. PGE2 did not serve as a substrate for
the enzyme. Various steroid compounds serve as the natural
substrates for the enzymes of the AKR family [22]. However,
the kcat/Km value for 5L-androstane-3,17-dione of human
PGFS was only 0.4% of that for PQ and that of the reverse
reaction with a substrate of 5L-androstan-3K-ol,17-one was
0.2%. These results suggest that PGD2 and 9K,11L-PGF2,
but not steroids, are the best substrates among natural sub-
stances for human PGFS.
3.3. Expression of human PGFS in lung and PBL
To clarify the physiological roles of PGFS in humans, we
used the anti-human PGFS antibody to examine the contri-
bution of PGFS to PGD2 11-ketoreductase activity in human
lung. The cytosol fraction of human lung (lane 2 in Fig. 2C)
gave a band at 36.8 kDa that cross-reacted with the anti-
human PGFS antibody, the same position as the band of
the puri¢ed recombinant PGFS (lane 1 in Fig. 2C). The
PGD2 11-ketoreductase activity in the cytosol of human
lung was 0.04 nmol/min/mg protein. As shown in Fig. 3,
whereas the control serum was almost ine¡ective, the activity
was dose-dependently absorbed by anti-human PGFS antise-
Fig. 1. Nucleotide sequence and deduced amino acid sequence of human PGFS. The asterisks indicate the stop codon and the underlined letters
in the nucleotide sequence show the polyadenylation signal. The arrows indicate PGFS-speci¢c primers used for RT-PCR of human PGFS
mRNA. The bold letters are the nucleotides and the amino acid residues of AKR1C3 di¡erent from those of human PGFS.
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rum and was completely lost at 100 Wg of serum. These results
suggest that V-hLuFS is a clone of human PGFS and that
PGD2 11-ketoreductase activity in human lung is ascribed
to the PGFS cloned here.
RT-PCR primers speci¢c for human PGFS were designed
on the basis of the cDNA sequence of PGFS shown in Fig. 1,
because human DDs of the AKR superfamily show more than
80% homology between each other. As shown in Fig. 4A, the
expected 136 bp band was speci¢cally ampli¢ed from lung
total RNA by RT-PCR with the PGFS-speci¢c primers
(PGFS-F4 and R5). Sequencing of the ampli¢ed DNA indi-
cated it to be that of human PGFS and not that of other
DDs. We also found that PGFS mRNA was expressed in
PBL as well as lung. As PGD2 is increased in alveolar lym-
phocytes as well as in macrophages, eosinophils and mast cells
after a challenge with an in£ammatory antigen [23^25], we
examined the e¡ect of Con A, which is considered to be a T
lymphocyte-speci¢c mitogen [26], on expression of PGFS
mRNA in PBL. As shown in Fig. 4B, 24 h incubation of
Fig. 2. SDS-PAGE (A) and Western blot analysis (B) of each puri¢-
cation step of the recombinant human PGFS and Western blot
analysis (C) of the cytosol fraction of human lung. (A) SDS-PAGE
(12%) silver stain and (B) Western blot analysis using the antiserum
against the puri¢ed recombinant human PGFS: the homogenate
(lane 1, 5 Wg for A and 0.2 Wg for B), the supernatant at 10 000Ug
(lane 2, 2 Wg for A and 0.1 Wg for B), the supernatant fraction at
100 000Ug (lane 3, 2 Wg for A and 0.1 Wg for B), the ammonium
sulfate fraction (lane 4, 2 Wg for A and 0.1 Wg for B), gel ¢ltration
fraction (lane 5, 0.2 Wg for A and 0.1 Wg for B) and DEAE-Toyo-
pearl fraction (lane 6, 0.1 Wg for A and 0.05 Wg for B) were loaded
into the indicated lanes. (C) Western blot analysis of the puri¢ed re-
combinant PGFS and of the cytosol fraction of human lung by use
of the antiserum against the recombinant human PGFS. Shown are
the results for the DEAE-Toyopearl fraction of the recombinant hu-
man PGFS (lane 1) and the supernatant fraction of human lung
from the 100 000Ug centrifugation (lane 2). The positions of the
molecular mass standards are shown: phosphorylase b (103 000), bo-
vine serum albumin (76 000), ovalbumin (49 000), carbonic anhy-
drase (33 200), soybean trypsin inhibitor (28 000) and lysozyme
(19 900).
Table 1
Substrate speci¢city of the puri¢ed recombinant human PGFS
Substrates Substrate concentration
(WM)
% Km
(WM)
Vmax
(Wmol/min/mg protein)
kcat
(min31)
kcat/Km
(min31 mM3)
Reduction
5L-Androstane-3,17-dione 100 4 3.1 0.05 1.9 640
5K-Androstane-3,17-dione 100 1
PQ 5 222 0.8 3.0 111 138 000
p-NB 100 100 77.4 1.8 65 840
PGD2 900 154 3.4 2.0 72 21 200
PGH2 40 20
PGE2 900 n.d.a
Oxidation
Acenaphtal 100 0.7
Dihydrotestosterone 100 0.1
cis-Androsterone 100 0.5
5L-Androstan-3K-ol,17-one 50 1.1 1 0.01 0.3 310
5L-Pregnane-3K,20K-diol 10 1
5K-Pregnane-3K,20K-diol 50 0.4
9K,11L-PGF2 150 307 134 6.56 242 1 810
PGF2K 150 1.2
The enzyme activities with various substrates were measured under standard conditions including the enzymes (0.2^1.0 Wg/0.5 ml of assay sys-
tem) as described under Section 2. Enzyme assays were performed initially at substrate concentrations indicated by ‘Substrate concentration’.
When enzyme activities were su⁄ciently high, kinetic constants, Km, Vmax and kcat, were determined. The NB reductase activity (1.8 U/mg pro-
tein) represents 100% activity.
an.d., not detected.
Fig. 3. Immunoabsorption of PGD2 11-ketoreductase activity in hu-
man lung. Various concentrations of the anti-human PGFS antise-
rum (b) or normal rabbit serum (a) were incubated with the cytosol
fraction of the human lung (650 Wg), prepared as described in Sec-
tion 2. The residual activity of PGD2 11-ketoreductase was deter-
mined and is shown as 100% of the initial activity (0.04 nmol/min/
mg protein).
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PBL with Con A almost completely suppressed the expression
of PGFS mRNA in PBL from one volunteer (no. 3) and had
smaller e¡ects on that of the mRNA in the two other volun-
teers.
4. Discussion
We have reported here the cloning of human PGFS cDNA
from human lung with bovine lung PGFS cDNA as a probe
and the result of the enzymatic characterization of the protein
expressed in E. coli. Moreover, we examined the expression of
PGFS in human lung and PBL. The expressed protein showed
PGFS activity and anti-human PGFS antiserum completely
absorbed the PGD2 11-ketoreductase activity associated
with PGFS in the cytosol fraction of human lung.
We characterized the enzymatic properties of the recombi-
nant PGFS in detail. The present study indicates that human
PGFS had the highest catalytic e⁄ciency for PQ, followed by
PGD2 and 9K,11L-PGF2, but that steroids did not serve as
substrates for this enzyme (Table 1). The kcat/Km value for
PGD2 was 11.7-fold higher than that for 9K,11L-PGF2 and
was 68.4-fold or more than those for various steroids. Human
PGFS had a carbonyl reductase activity similar to that of
bovine PGFS. However, PGD2 and 9K,11L-PGF2 were the
natural substrates for human PGFS and the enzyme preferred
the reduction of PGD2 to the oxidation of 9K,11L-PGF2. The
Km value for PGD2 was about 3 WM, indicating that the
enzyme has the high a⁄nity for PGD2. Arg91 and Arg223
were conserved between human lung PGFS and bovine liver
PGFS, the latter of which also has a low Km value (10 WM)
for PGD2 [11]. When Arg91 and Arg223 of bovine liver PGFS
were changed to the Gln and Leu, respectively, of bovine lung
PGFS, which has a high Km value for PGD2 (120 WM), the
Km values of these mutants were increased from 15 WM to 145
WM and 180 WM, respectively [11]. Our present ¢nding of a
low Km value for human PGFS agrees with our previous
¢nding [11] that Arg91 and Arg223 were the essential amino
acid residues for a low Km value.
PGFS belongs to the AKR superfamily classi¢ed by Jez et
al. [22], based on the similarity of the amino acid sequence.
AKR1C3 was reported to be human liver 3K-HSD type II
[13,14]. The deduced amino acid sequences of human PGFS
and the cDNA clone KIAA0119 [17] were identical and dif-
fered by only two residues (Lys75 and Met175) from the se-
quence reported for AKR1C3 [13]. Matsuura et al. [15] re-
ported that AKR1C3 prepared by site-directed mutagenesis of
KIAA0119 showed the same enzymatic properties as the ex-
pressed protein of KIAA0119 and that AKR1C3 acted as a
PGD2 11-ketoreductase. This report suggests that Lys75 and
Met175 have no e¡ect on the enzyme activity. Although PGD2
11-ketoreductase activity is associated with PGFS, they did
not report whether KIAA0119 and AKR1C3 have the enzy-
matic properties of PGFS described previously [5]. The results
on human PGFS in this paper indicate that AKR1C3 acts as
PGFS and these results together with the reports described
above suggest that PGFS is involved in metabolism of xeno-
biotics as well as PGD2 and 9K,11L-PGF2 in human liver.
PGD2 is the major cyclooxygenase metabolite produced by
mast cells in response to IgE-dependent stimulation and it is
considered to be an important mediator in various allergic
diseases such as allergic rhinitis, atopic asthma, allergic con-
junctivitis and atopic dermatitis [27]. Although there are nu-
merous reports on the contributions of PGD2 to the patho-
genesis of various allergic diseases on the basis of local
production of PGD2 and of increased urinary excretion of
9K,11L-PGF2 after an allergen challenge [28], this study pro-
vides the ¢rst experimental evidence that PGFS is involved in
the metabolism of PGD2 in human tissues. More responsive-
ness to PGD2 in asthmatic and atopic subjects than in normal
subjects was previously ascribed to a cholinergic mechanism
[24]. Here, we demonstrated that the expression of PGFS
mRNA was markedly suppressed by a T cell mitogen, Con
A, in three volunteers. Since PGFS mRNA is highly expressed
in lymphocytes and the human mast cell is capable of releas-
ing cytokines that have the capacity to initiate and maintain a
chronic in£ammatory response, the present study raises the
possibility that PGFS expressed in lymphocytes may modulate
the metabolism of PGD2 in an in£ammatory site and contrib-
ute to the pathogenesis of patients with allergic diseases. It is
interesting that the PGFS gene has been assigned to chromo-
some 10 p14-p15, close to the K-chain genes of IL-2 and IL-15
receptors [29] (data not shown), in agreement with the place-
ment of KIAA0119 cDNA at the sequence-tagged site
SGC31479 between WI-5839 and WI-598 at the top of human
chromosome 10 [12]. Cloning of human PGFS cDNA and the
development of RT-PCR speci¢c for PGFS may provide the
tools required for in vivo and in vitro studies to further under-
stand the gene regulation of PGFS in human tissues and
pathophysiological roles of this enzyme in allergic diseases.
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